Check-Cap Ltd (NASDAQ:MBAI – Free Report) – Investment analysts at Northland Securities issued their FY2026 earnings per share (EPS) estimates for shares of Check-Cap in a report issued on Monday, September 28th. Northland Securities analyst M. Latimore expects that the company will earn ($0.02) per share for the year. Northland Securities currently has a “Outperform” rating and a $10.00 target price on the stock. The consensus estimate for Check-Cap’s current full-year earnings is ($0.02) per share. Northland Securities also issued estimates for Check-Cap’s FY2027 earnings at $0.00 EPS, FY2028 earnings at $0.19 EPS and FY2029 earnings at $0.58 EPS.
MBAI has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Check-Cap in a report on Tuesday, July 21st. Zacks Research upgraded Check-Cap to a “hold” rating in a research note on Tuesday. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $10.00.
Check-Cap Price Performance
Shares of MBAI opened at $3.16 on Wednesday. Check-Cap has a one year low of $3.07 and a one year high of $27.44. The firm has a market capitalization of $4.36 million, a P/E ratio of -0.22 and a beta of 0.66. The business has a fifty day moving average of $6.96 and a 200 day moving average of $9.31.
About Check-Cap
Check-Cap Ltd. was an Israel-based medical diagnostics company focused on developing noninvasive technologies for colorectal cancer screening. Its lead product, C-Scan, was an ingestible, capsule-based imaging system designed to examine the colon for polyps and other abnormalities without requiring the extensive bowel preparation typically associated with conventional colonoscopy.
The C-Scan system was intended to combine a disposable capsule with an external tracking and data-collection system, allowing physicians to review images of the gastrointestinal tract after the capsule passed through the body.
Featured Articles
- Five stocks we like better than Check-Cap
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.
